loratadine / Generic mfg. - LARVOL DELTA

Repurposing loratadine to reverse colistin resistance in Klebsiella pneumoniae through targeting lipid A modification. (PubMed, Emerg Microbes Infect) - "In addition, the combination of loratadine and colistin disrupts the double-layer membrane barrier, leading to proton motive force (PMF) dysregulation, reduced intracellular ATP levels, and impaired efflux pump activity. Collectively, this study highlights the potential of drug repurposing as an effective strategy to combat antimicrobial resistance and provides a foundation for the development of combination therapies against multidrug-resistant pathogens."

Journal • Infectious Disease • Pneumonia

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov) - P4 | N=94 | Recruiting | Sponsor: Emory University | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Allergy • Hematological Malignancies • Multiple Myeloma • Oncology

The effects of oral second-generation antihistamines on psychomotor, cognitive, and academic performance: A systematic review (AAAAI 2026) - "Search terms included oral second-generation antihistamines approved for use in the United States and Canada, specifically cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine, bilastine, and rupatadine, with the terms psychomotor, cognitive, and academic performance. Varying effects were found across these categories. Understanding these outcomes will better inform patient care via appropriate selection of antihistamines to minimize disruption on daily activities."

Review • Anesthesia

In-vitro and In-vivo CYP3A4 Variants: Neratinib Metabolism and Drug Interaction Risk. (PubMed, Chem Biol Interact) - "Furthermore, the differential inhibitory effects of loratadine toward CYP3A4.1 and CYP3A4.34 underscore the role of CYP3A4 genetic polymorphisms in modulating the inhibitory potency of loratadine toward neratinib. In conclusion, our study suggests that coadministration of loratadine and genetic polymorphisms in CYP3A4 can significantly influence neratinib metabolism, necessitating caution regarding potential drug-drug interactions in clinical settings."

Journal • Preclinical • CYP3A4

Case Report: A case of post-viral inflammatory insomnia: observed sleep restoration associated with histamine-targeted interventions and implications for mast cell pathways. (PubMed, Front Sleep) - "Despite optimal CPAP use and multiple pharmacological trials for sleep disturbance (zolpidem, trazodone, gabapentin, diazepam, lemborexant), Oura Ring data demonstrated persistently low sleep scores, often in the 30-40 range, and minimal REM and deep sleep...At 4-week follow-up, lingering daytime fatigue and patient-reported cognitive fog prompted additional dietary modification to a low-histamine pattern and the addition of loratadine (10 mg AM) and famotidine (20 mg BID)...A multi-component intervention targeting histamine pathways, including antihistamine therapy, environmental modification, and dietary adjustment, was associated with rapid and sustained normalization of objective sleep metrics in this patient. These findings highlight the importance of evaluating immune and inflammatory contributors in patients with refractory insomnia and support further investigation of mast cell-related pathways in translational sleep medicine."

Journal • CNS Disorders • Fatigue • Inflammation • Insomnia • Sleep Disorder

Lecanemab over a two-year duration: Key insights from a regional specialty medical center. (PubMed, J Prev Alzheimers Dis) - "Our findings suggest that ARIA is a significant concern especially in patients who are ε4 homozygous. Close monitoring of patients who are ε4 carriers is recommended to recognize any complications that may ensue."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Pain

Ecotoxicological impact of removing pharmaceutical residues from aqueous solutions using recycled ultrafiltration membranes. (PubMed, Sci Total Environ) - "This study evaluated the efficiency of recycled ultrafiltration membranes modified with titanium dioxide (TiO2) and graphene oxide (GO) in the removal of pharmaceutical compounds containing betamethasone, ketoprofen, fenofibrate, fluconazole, loratadine, and prednisone. Higher frequencies of clastogenic and aneugenic abnormalities were also observed in the meristematic cells for the permeate samples from the third recycled membrane modified with TiO2, graphene oxide, and photocatalysis. The effectiveness of the ultrafiltration membranes in eliminating toxic substances was confirmed by the ecotoxicological tests performed in this study."

Journal

Mechanistic insights into drug loading effect on dissolution performance of Loratadine-Soluplus® amorphous solid dispersions. (PubMed, J Pharm Sci) - "SEM imaging suggested similar surface morphology before and after partial dissolution, but EDX elemental analysis revealed congruent drug-polymer release at low DL and incongruent (polymer-first) release at high DL. These findings identify an optimum drug-loading window where ASD generates and sustains supersaturation status for loratadine, and highlight mechanistic links between DL, LLPS droplet size, and incongruent release that explain reduced performance at higher loadings."

Journal

Prefrontal cortex-extracellular vesicle RNAs coupling in alcohol use disorder: towards non-invasive biomarkers and targeted therapeutics. (PubMed, Artif Cells Nanomed Biotechnol) - "Computational drug repurposing identified loratadine, doxepin, citalopram and imipramine as promising therapeutic candidates targeting SERPINA3. Collectively, this work delineated PFC signature genes, proposed a EVs-supported brain-periphery molecular crosstalk, and provided translatable biomarkers and repurposable candidates for AUD precision medicine."

Biomarker • Journal • Addiction (Opioid and Alcohol) • IL17A • SERPINA3

Rebound Pruritus and Urticaria Post-discontinuation of Chronic Cetirizine Use: A Case Report. (PubMed, Cureus) - "Through shared decision-making, he was switched to loratadine and chlorpheniramine for three days before transitioning to an "as-needed" regimen without recurrence of pruritus or urticaria. While the pathophysiology of rebound pruritus and urticaria post-discontinuation of chronic cetirizine use remains poorly understood, this case report suggests that the phenomenon may be drug-specific rather than a class-specific adverse effect. Larger studies are necessary to confirm if a temporary switch and short-term bridging with alternative antihistamines offer a safer discontinuation strategy for patients on chronic cetirizine."

Journal • Allergic Rhinitis • Atopic Dermatitis • Cardiovascular • Dermatology • Dyslipidemia • Hypertension • Immunology • Inflammation • Pruritus • Urticaria

Management Considerations for Dermatologic Toxicities Associated With Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (IMW 2023) - P1, P2 | "Management of dermatologic AEs included a heavy moisturizer for general dryness; ammonium lactate 12% lotion twice daily (BID) for hand and foot peeling; loratadine 10 mg oral tablet daily for 3–5 days post dose and triamcinolone 0.1% cream BID for pruritus, injection-site reaction, and rash; and nail hardeners, topical vitamin E oil, and triamcinolone 0.025% ointment for nail thinning and peeling. Talquetamab is an effective therapy for patients with RRMM. Skin and nail AEs are common but are primarily low grade with no discontinuations. Appropriate management, education, and supportive care ensure that patients can stay on treatment to receive optimal benefit from talquetamab."

Clinical • Dermatology • Hematological Malignancies • Multiple Myeloma • Oncology • Pruritus

Remibrutinib (Rhapsido) for chronic spontaneous urticaria. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Multi-Target Therapeutic Effects of YuPingTongQiao (YPTQ) in Allergic Rhinitis: A Traditional Chinese Medicine Restoring Dysregulated TFR Cells and Reinforcing Epithelial Barrier Integrity. (PubMed, J Inflamm Res) - "YPTQ offers a safe, effective, and multi-target therapeutic option for AR, addressing both immune dysregulation and epithelial dysfunction. Its superior efficacy compared to Loratadine and excellent safety profile highlight its potential as a novel alternative or adjunct to conventional treatments for AR."

IO biomarker • Journal • Allergic Rhinitis • Immunology • Inflammation • CLDN1 • CTLA4 • IL13 • IL33 • IL4 • IL5 • MUC2

Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers (clinicaltrials.gov) - P=N/A | N=88 | Recruiting | Sponsor: Alexandria University | Enrolling by invitation ➔ Recruiting | Initiation date: Dec 2025 ➔ Mar 2025

Enrollment status • Trial initiation date • Hematological Malignancies • Musculoskeletal Pain • Neutropenia • Oncology • Pain

Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers (clinicaltrials.gov) - P=N/A | N=88 | Enrolling by invitation | Sponsor: Alexandria University

New trial • Hematological Malignancies • Musculoskeletal Pain • Neutropenia • Oncology • Pain

Determination of 116 Pharmaceuticals and Personal Care Products in Water by Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry. (PubMed, J Sep Sci) - "Notably, to the best of our knowledge, this study represented the first reported detection of melamine, loratadine, aldosterone, and levothyroxine sodium in aquatic environments. In particular, melamine was detected in aquatic environment for the first time, thus expanding the understanding of PPCPs' pollution status."

Journal • Pain

Baicalin Nasal Irrigation Mitigates Allergic Rhinitis in Mice by Inhibiting Eosinophil Chemotaxis. (PubMed, Int Arch Allergy Immunol) - "Methods OVA-induced BALB/c mice (n=17 per group) were randomized into six groups: control, AR model, baicalin, loratadine, combination of baicalin and loratadine, and excipient...Transcriptomic analysis revealed modulation of chemokines (CCL6, CCL8, and CCL24) involved in eosinophil chemotaxis, a finding corroborated by PPI analysis and immunohistochemistry. Conclusion Baicalin nasal irrigation inhibits eosinophil chemotaxis and alleviates AR symptoms, highlighting its potential as a novel local therapeutic strategy for AR."

Journal • Preclinical • Allergic Rhinitis • Immunology • Inflammation • CCL8 • MUC5AC • OCLN • TJP1

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy (ASH 2025) - P1, P3 | "All patients received"enhanced" premeds with: loratadine (10 mg, PO), famotidine (20 mg, PO) and montelukast (10 mg, PO)daily on Day 1-5; plus acetaminophen (975mg, PO), hydrocortisone (200 mg, IV), diphenhydramine (25mg, IV) and famotidine (20 mg, IV) on Day 4 (30-45 mins pre-M). Meanwhile,enhanced premeds were associated with a low rate of AEs relative to standard premeds. Ongoingextended immunophenotyping may shed insight into the mechanism of impaired HSC mobilization post-quad induction, possibly via targeted depletion of a large population of CD38+ HSCs within the CD34+graft."

Clinical • Dermatology • Hematological Malignancies • Multiple Myeloma • Pruritus • CD34

Efficacy of a Combination Therapy of Montelukast and Antihistamines in Allergic Rhinitis: A Systematic Review and Network Meta-Analysis. (PubMed, Allergy Asthma Immunol Res) - "The treatment strategies included montelukast alone, antihistamine monotherapies (loratadine, desloratadine, levocetirizine, and fexofenadine), their respective combinations with montelukast, including bilastine. Although some comparisons require cautious interpretation, montelukast-based combination therapy demonstrated greater efficacy than monotherapy for multiple AR symptoms. These results highlight the importance of selecting therapeutic strategies based on the predominant symptom profile of individual patients."

Journal • Retrospective data • Review • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov) - P4 | N=94 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Enrollment open • Allergy • Hematological Malignancies • Multiple Myeloma • Oncology

The use of antihistamine and antihistamine-like drugs for cancer-related pain: a narrative review. (PubMed, Support Care Cancer) - "Analysis of these studies demonstrated meaningful evidence that antihistamine and antihistamine-like drugs may offer some benefit for treating cancer-related pain."

Journal • Review • Mucositis • Oncology • Pain • Peripheral Neuropathic Pain • Stomatitis

Development of a UHPLC-MS/MS method for the quantification of DMPC and DMPG in rats and its pharmacokinetic and tissue distribution application. (PubMed, J Pharm Biomed Anal) - "DMPC, DMPG and Loratadine (internal standard, IS) were separated on an Agilent ZORBAX Extend-C18 column (2.1 mm × 50 mm, 3.5 μm particle size) by using gradient elution consisting of isopropanol-acetonitrile (90:10, v/v, 10 mM ammonium formate and 0.1 % formic acid) and water (10 mM ammonium formate and 0.1 % formic acid) at a flow rate of 0.3 mL/min in 4.0 min...However, after intravenous administration of the excipients, their half-lives were 3.5 h and 1.1-2.3 h. The observed prolongation of DMPC's half-life and concomitant shortening of DMPG's half-life are attributed to the distinct physicochemical properties of the nanoparticles."

Journal • PK/PD data • Preclinical

Modifying Mast Cell Response to Control Inflammation and Optimize Repair in Reperfused Myocardial Infarction (AHA 2025) - "In the present study we tested whether loratadine, a commonly used over-the-counter antihistamine and MC stabilizer, attenuates MVO and augments early inflammation in reperfused MIs. Twelve pigs underwent a closed-chest 90-minute ischemia-reperfusion of the left anterior descending artery and were followed through Day 5-Week 8 with LGE, cine and 18FDG-PET/MRI... Our seemingly paradoxical findings of MC stabilizer-augmented initial inflammatory response and lower subsequent ventricular volumes indicate that fine-tuning of MC degranulation post-MI could be a novel therapeutic strategy for optimized remodeling of reperfused MIs."

Cardiovascular • Inflammation • Myocardial Infarction • Reperfusion Injury

Preliminary efficacy and safety profile of dual histamine blockade on preventing filgrastim-associated bone pain in breast cancer patients: Randomized controlled trial. (PubMed, Br J Clin Pharmacol) - "The prophylactic dual histamine blockade strategy, when administered alongside filgrastim, could significantly ameliorate the incidence and severity of G-CSF-associated bone pain, and therefore improve patient's QoL. Further larger clinical studies are warranted to validate the clinical utility of this novel approach."

Journal • Breast Cancer • Musculoskeletal Pain • Oncology • Pain • Solid Tumor

Comparing Antihistamine Premedication Regimens for Preventing Rituximab-Associated Infusion Reactions in Hemato-Oncology Patients: A Retrospective Analysis (ASH 2024) - "Results : Three antihistamines were identified : diphenhydramine 50 mg, loratadine 10 mg, and cetirizine 10 mg. Using one dose of less sedating second-generation antihistamines may improve patient safety without compromising clinical efficacy. By recognizing second-generation antihistamines as a safer and equally efficacious option for rituximab premedication, standard antihistamine prescribing practices should be re-evaluated with the goal of optimizing patient safety and medication burden."

Retrospective data • Hematological Malignancies • Oncology